Premium
The specificity of potassium canrenoate, a steroidal antidysrhythmic drug
Author(s) -
Yeh Billy K.,
Sung Pei-Kun,
Lazzara Ralph
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt19741661014
Subject(s) - ouabain , chemistry , barium chloride , ventricular tachycardia , medicine , quinidine , potassium , bigeminy , pentobarbital , anesthesia , endocrinology , pharmacology , sodium , organic chemistry
The antidysrhythmic property of potassium canrenoate [potassium 3‐(3‐oxo‐17β‐hydroxy‐4, 6‐androstadien‐17α‐yl) propanoatel was studied in ventricular dysrhythmias induced by ouabain, norepinephrine, barium, and strontium, as well as ligation of the anterior descending coronary artery in dogs anesthetized with sodium pentobarbital. Potassium canrenoate (KC) (12 mg/kg) was effective in abolishing the ouabain‐induced ventricular bigeminy and ventricular tachycardia without significantly altering the inotropic response of the heart to ouabain. Our previous data indicate that equimolar amounts of potassium chloride were ineffective under the same circumstances. KC (12 mg/kg) had no effect on ventricular dysrhythmias caused by norepinephrine and myocardial infarction. Up to 30 mg/kg KC did not suppress ventricular tachycardia induced by barium or strontium. The canrenoate molecule appears to be a specific antagonist to the electrophysiologic toxicity of cardiac glycosides.